Lineage Cell Therapeutics, Inc.
For the period ended Sep 30, 2025. Filed Nov 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 6, 2025
LCTX$1.08+5.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Shareholders' Equity
| Three Months Ended September 30, 2025 | ||||||
|---|---|---|---|---|---|---|
| Accumulated | ||||||
| Other · Total | ||||||
| Common Shares · Accumulated · Noncontrolling · Comprehensive · Shareholders’ | ||||||
| Shares | Amount | Deficit | Deficit | Income / (Loss) | Equity | |
| BALANCE - June 30, 2025 | 228,356 | $490,551 | $(438,068) | $(1,273) | $(4,098) | $47,112 |
| Shares issued through ATM financing | 1,000 | 1,315 | — | — | — | 1,315 |
| Financing related fees | — | (42) | — | — | — | (42) |
| Shares issued upon exercise of stock options | 622 | 646 | — | — | — | 646 |
| Shares issued upon exercise of warrants | 350 | 319 | — | — | — | 319 |
| Derivative warrant liability reclassified to share capital on exercise of warrants | — | 187 | — | — | — | 187 |
| Stock-based compensation | — | 1,199 | — | — | — | 1,199 |
| Unrealized gain on marketable debt securities | — | — | — | — | 1 | 1 |
| Foreign currency translation adjustment | — | — | — | — | (189) | (189) |
| Net income (loss) | — | — | (29,781) | 29 | — | (29,752) |
| BALANCE - September 30, 2025 | 230,328 | $494,175 | $(467,849) | $(1,244) | $(4,286) | $20,796 |
| Three Months Ended September 30, 2024 | ||||||
|---|---|---|---|---|---|---|
| Accumulated | ||||||
| Other · Total | ||||||
| Common Shares · Accumulated · Noncontrolling · Comprehensive · Shareholders’ | ||||||
| Shares | Amount | Deficit | Deficit | Income / (Loss) | Equity | |
| BALANCE - June 30, 2024 | 188,824 | $467,928 | $(397,158) | $(1,425) | $(2,470) | $66,875 |
| Shares issued upon exercise of stock options | 13 | 10 | — | — | — | 10 |
| Stock-based compensation | — | 1,330 | — | — | — | 1,330 |
| Unrealized gain on marketable debt securities | — | — | — | — | 12 | 12 |
| Foreign currency translation adjustment | — | — | — | — | (432) | (432) |
| Net income (loss) | — | — | (3,034) | 33 | — | (3,001) |
| BALANCE - September 30, 2024 | 188,837 | $469,268 | $(400,192) | $(1,392) | $(2,890) | $64,794 |
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY
| Nine Months Ended September 30, 2025 | ||||||
|---|---|---|---|---|---|---|
| Accumulated | ||||||
| Other · Total | ||||||
| Common Shares · Accumulated · Noncontrolling · Comprehensive · Shareholders’ | ||||||
| Shares | Amount | Deficit | Deficit | Income / (Loss) | Equity | |
| BALANCE - December 31, 2024 | 220,416 | $484,722 | $(403,465) | $(1,369) | $(2,876) | $77,012 |
| Shares issued through registered direct financing | 7,895 | 3,795 | — | — | — | 3,795 |
| Shares issued through ATM financing | 1,000 | 1,315 | — | — | — | 1,315 |
| Financing related fees | — | (448) | — | — | — | (448) |
| Shares issued upon vesting of restricted stock units, net of shares retired to pay employees’ taxes | 45 | (15) | — | — | — | (15) |
| Shares issued upon exercise of stock options | 622 | 646 | — | — | — | 646 |
| Shares issued upon exercise of warrants | 350 | 319 | — | — | — | 319 |
| Derivative warrant liability reclassified to share capital upon exercise of warrants | — | 187 | — | — | — | 187 |
| Stock-based compensation | — | 3,654 | — | — | — | 3,654 |
| Unrealized loss on marketable debt securities | — | — | — | — | (4) | (4) |
| Foreign currency translation adjustment | — | — | — | — | (1,406) | (1,406) |
| Net income (loss) | — | — | (64,384) | 125 | — | (64,259) |
| BALANCE - September 30, 2025 | 230,328 | $494,175 | $(467,849) | $(1,244) | $(4,286) | $20,796 |
| Nine Months Ended September 30, 2024 | ||||||
|---|---|---|---|---|---|---|
| Accumulated | ||||||
| Other · Total | ||||||
| Common Shares · Accumulated · Noncontrolling · Comprehensive · Shareholders’ | ||||||
| Shares | Amount | Deficit | Deficit | Income / (Loss) | Equity | |
| BALANCE - December 31, 2023 | 174,987 | $451,343 | $(384,856) | $(1,396) | $(3,068) | $62,023 |
| Shares issued through registered direct financings | 13,462 | 14,000 | — | — | — | 14,000 |
| Shares issued through ATM financing | 56 | 70 | — | — | — | 70 |
| Financing related fees | — | (113) | — | — | — | (113) |
| Shares issued upon vesting of restricted stock units, net of shares retired to pay employees’ taxes | 45 | (23) | — | — | — | (23) |
| Shares issued upon exercise of stock options | 287 | 229 | — | — | — | 229 |
| Stock-based compensation | — | 3,762 | — | — | — | 3,762 |
| Unrealized gain on marketable debt securities | — | — | — | — | 5 | 5 |
| Foreign currency translation adjustment | — | — | — | — | 173 | 173 |
| Net income (loss) | — | — | (15,336) | 4 | — | (15,332) |
| BALANCE - September 30, 2024 | 188,837 | $469,268 | $(400,192) | $(1,392) | $(2,890) | $64,794 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.